Immunic (IMUX) Competitors

Immunic (NASDAQ:IMUX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Is IMUX or ERAS more profitable?

Erasca's return on equity of -42.26% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
Erasca	N/A	-42.26%	-34.97%

Do insiders & institutionals have more ownership in IMUX or ERAS?

51.8% of Immunic shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 3.0% of Immunic shares are owned by company insiders. Comparatively, 21.5% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more risk and volatility, IMUX or ERAS?

Immunic has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Which has preferable earnings & valuation, IMUX or ERAS?

Erasca is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61M	-$1.23	-0.80
Erasca	N/A	N/A	-$125.04M	-$0.74	-1.61

Does the media refer more to IMUX or ERAS?

In the previous week, Immunic had 7 more articles in the media than Erasca. MarketBeat recorded 12 mentions for Immunic and 5 mentions for Erasca. Erasca's average media sentiment score of 0.91 beat Immunic's score of 0.28 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor IMUX or ERAS?

Immunic received 79 more outperform votes than Erasca when rated by MarketBeat users. However, 74.36% of users gave Erasca an outperform vote while only 64.67% of users gave Immunic an outperform vote.

Company	Underperform	Outperform
Immunic	Outperform Votes 108 64.67%	Underperform Votes 59 35.33%
Erasca	Outperform Votes 29 74.36%	Underperform Votes 10 25.64%

Do analysts recommend IMUX or ERAS?

Immunic currently has a consensus price target of $13.20, suggesting a potential upside of 1,236.03%. Erasca has a consensus price target of $4.83, suggesting a potential upside of 306.16%. Given Immunic's stronger consensus rating and higher possible upside, equities analysts plainly believe Immunic is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Erasca	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Immunic beats Erasca on 8 of the 15 factors compared between the two stocks.